Pharming Group N.V. confirms it will report its preliminary (unaudited) third quarter 2023 financial results, for the period ended September 30, on Thursday, October 26, 2023.

Pharming Group N.V. announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM agenda.

Pharming shortlisted in two categories, including “Biotech Company of the Year” and “Best New Drug”

Pharming Group N.V. announces that Pharming’s management will participate in the following investor conferences in the U.S. in the month of September:

Pharming Group N.V. announces it will hold an Extraordinary General Meeting of Shareholders (EGM) on Monday, September 25, 2023 at 14:00 CEST.

Single-arm Phase III study in Japan evaluating leniolisib in patients aged 12 years and older with APDS, a rare primary immunodeficiency

Pharming Group N.V. presents its preliminary (unaudited) financial report for the second quarter and first half ended June 30, 2023.

Pharming Group N.V. announces today that the Board of Directors has nominated Dr. Richard Peters to become Pharming’s new Chairman.

Pharming Group N.V. confirms it will report its preliminary (unaudited) second quarter and first half 2023 financial results, for the period ended June 30, on Thursday, August 3, 2023.

Pharming is delighted to announce that CEO Sijmen de Vries was the winner of the Chief Executive of the Year Award at the 2023 European Mediscience Awards in London on Thursday evening. Scroll down for the Dutch translation.